An observational study in Dengue Vaccines, sponsored by Fundación Vacunar. Completed at 1 site in Argentina. Open to participants aged 4 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Fundación Vacunar · Observational
The TAK-003 vaccine, Qdenga, developed by Takeda, was approved by ANMAT in April 2023 and has been available in Argentina since November 2023 for individuals from 4 years old and without limit of age. Clinical trials demonstrate that Qdenga has a favorable safety profile, adequate immunogenicity for all four serotypes, and efficacy in preventing severe dengue in seropositive and seronegative subjects. However, there are currently limited real-world safety studies on TAK-003, particularly for adults over 60 years old.
The aim of this study is to evaluate Adverse Events Supposedly Attributed to Vaccination and Immunization (AEFI) for TAK-003 vaccine in vaccinated people at private vaccination centers in Buenos Aires metropolitan area.
279 studies on the registry are indexed under Dengue; 45 are open to participants now.
This study's enrollment of 112,345 is above the median of 595 across 78 observational studies indexed under Dengue.
Browse Dengue studies →Fundación Vacunar is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
People vaccinated with dengue vaccine, TAK-003 at private vaccination centers in Buenos Aires, Argentina
Exclusion Criteria:
Participants from 4 years of age with no upper limit in accordance with ANMAT approval and for whom safety data is available through the Vacunar centers passive surveillance systems
Incidence of AEFI
The incidence of adverse events following immunization (AEFI) will be calculated in terms of the number of notifications per 1,000 doses administered.
Time frame: 42 days
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.